Introduction

The global healthcare community faces an unprecedented crisis in antimicrobial resistance. Among the most concerning developments is the rise of pan-resistant gram-negative bacteria, organisms that demonstrate resistance to virtually all available antibiotics. These pathogens represent the extreme end of the antimicrobial resistance spectrum, where conventional treatment approaches prove inadequate.

Gram-negative bacteria possess inherent structural features that facilitate the development of resistance. Their double membrane structure provides natural barriers to many antimicrobial agents. The outer membrane acts as a selective barrier, while efflux pumps actively remove antibiotics from the bacterial cell. These characteristics, combined with the acquisition of multiple resistance genes, create formidable opponents in clinical practice.

The World Health Organization has identified carbapenem-resistant gram-negative bacteria as critical priority pathogens requiring urgent attention for new antibiotic development. The clinical reality, however, shows that resistance has outpaced drug development, leaving patients with infections for which there are no effective treatment options.

This crisis extends beyond individual patient care. Healthcare institutions struggle with infection control measures, increased length of stay, and elevated mortality rates associated with pan-resistant infections. The economic burden encompasses direct treatment costs, extended hospitalizations, and the implementation of enhanced infection prevention protocols.

Understanding the current landscape of pan-resistant gram-negative bacteria requires examining multiple factors. These include the molecular mechanisms driving resistance, the epidemiological patterns of spread, the clinical manifestations and outcomes, and the emerging therapeutic strategies to address these challenging infections.

Defining Pan-Resistance in Gram-Negative Bacteria

Pan-resistance represents the most extreme form of antimicrobial resistance, in which organisms demonstrate resistance to all available antibiotics in their testing panel. The European Center for Disease Prevention and Control defines pan-drug-resistant bacteria as those that are non-susceptible to all agents across all antimicrobial categories. This definition provides clinical clarity but also highlights the severity of these infections.

The terminology surrounding extreme resistance patterns requires careful consideration. Extensively drug-resistant organisms retain susceptibility to only one or two antimicrobial categories. Pan-resistant organisms, by contrast, show resistance across all tested categories. This distinction matters clinically, as extensively drug-resistant infections may still respond to last-resort agents, while pan-resistant infections leave clinicians without proven therapeutic options.

Gram-negative bacteria most commonly associated with pan-resistance include Acinetobacter baumannii, Pseudomonas aeruginosa, and members of the Enterobacteriaceae family, particularly Klebsiella pneumoniae and Escherichia coli. Each species presents unique resistance mechanisms and clinical challenges.

Acinetobacter baumannii has emerged as particularly problematic in healthcare settings. This organism demonstrates remarkable adaptability, rapidly acquiring resistance genes through horizontal transfer. Its ability to survive in harsh environmental conditions facilitates nosocomial spread. Pan-resistant A. baumannii strains have been reported globally, with some regions experiencing endemic circulation.

Pseudomonas aeruginosa possesses intrinsic resistance mechanisms that provide natural protection against many antimicrobials. The acquisition of additional resistance determinants can rapidly progress these organisms toward pan-resistance. Hospital-acquired P. aeruginosa infections frequently involve multidrug-resistant strains, with some progressing to pan-resistance during treatment.

Carbapenemase-producing Enterobacteriaceae represent another critical category. These organisms produce enzymes that hydrolyze carbapenem antibiotics, historically considered last-resort agents for the treatment of gram-negative infections. When carbapenemase production combines with other resistance mechanisms, pan-resistance may result.

Mechanisms of Resistance in Pan-Resistant Gram-Negatives

The development of pan-resistance requires the accumulation of multiple resistance mechanisms within a single organism. Understanding these mechanisms provides insight into both the challenge these infections present and potential targets for new therapeutic approaches.

Beta-lactamase production represents a cornerstone of gram-negative resistance. Extended-spectrum beta-lactamases hydrolyze penicillins, cephalosporins, and monobactams. Carbapenemases add the ability to hydrolyze carbapenem antibiotics. When organisms produce multiple beta-lactamases with different substrate specificities, they achieve resistance to virtually all beta-lactam antibiotics.

The classification of beta-lactamases helps predict resistance patterns and potential treatment options. Class A carbapenemases, including KPC enzymes, are serine-based and may retain susceptibility to certain beta-lactamase inhibitor combinations. Class B metallo-beta-lactamases require zinc for activity and demonstrate resistance to all beta-lactams except monobactams. Class D oxacillinases, particularly OXA-type carbapenemases, show varied substrate specificities but frequently confer carbapenem resistance.

Efflux pump overexpression provides another mechanism for achieving broad-spectrum resistance. These protein complexes actively transport antimicrobials out of the bacterial cell, reducing intracellular drug concentrations below therapeutic levels. Gram-negative bacteria possess multiple efflux systems with overlapping substrate specificities. Overexpression of these systems can confer resistance to multiple antibiotic classes simultaneously.

Porin loss or modification affects antibiotic entry into gram-negative bacteria. Porins are protein channels that allow small molecules, including antibiotics, to cross the outer membrane. Mutations that reduce porin expression or alter channel selectivity can prevent antibiotics from reaching their intracellular targets. When combined with other resistance mechanisms, porin modifications contribute to the development of pan-resistance.

Target site modifications represent another resistance strategy. Mutations in the binding sites for fluoroquinolones, aminoglycosides, and other antibiotics can render drugs ineffective. Methylation of ribosomal RNA prevents aminoglycoside binding. These modifications, when present alongside other resistance mechanisms, contribute to the pan-resistant phenotype.

Table 1: Common Resistance Mechanisms in Pan-Resistant Gram-Negative Bacteria

Resistance Mechanism	Affected Antibiotic Classes	Primary Organisms	Clinical Impact
Carbapenemase Production	Beta-lactams including carbapenems	Klebsiella, Acinetobacter, Pseudomonas	Loss of last-resort beta-lactams
Efflux Pump Overexpression	Multiple classes	Pseudomonas, Acinetobacter	Broad-spectrum resistance
Porin Loss	Beta-lactams, fluoroquinolones	Enterobacteriaceae	Reduced drug penetration
16S rRNA Methylation	Aminoglycosides	Various gram-negatives	Aminoglycoside resistance
Quinolone Resistance	Fluoroquinolones	Multiple species	Loss of a broad-spectrum oral option

Epidemiology and Global Distribution

The epidemiology of pan-resistant gram-negative bacteria varies substantially across geographic regions, healthcare settings, and patient populations. Understanding these patterns helps inform prevention strategies and guides empirical treatment decisions in high-risk scenarios.

Healthcare-associated infections serve as the primary reservoir for pan-resistant gram-negative bacteria. Intensive care units experience the highest prevalence, reflecting the vulnerable patient populations, frequent antibiotic use, and invasive procedures common in these settings. Patients with prolonged hospitalizations, multiple antibiotic exposures, and invasive devices face an elevated risk of acquiring pan-resistant organisms.

Geographic distribution shows marked regional variation. Mediterranean countries have reported high rates of carbapenemase-producing Enterobacteriaceae, particularly organisms harboring KPC and OXA-type enzymes. Asian countries have experienced a rapid spread of NDM-producing organisms. The United States has seen an increasing prevalence of CRE organisms, with some progressing to pan-resistance.

An interesting observation occurred at a medical conference, where an infectious disease specialist joked that their hospital’s antibiogram was beginning to look like a checkerboard of resistance, with more red squares indicating resistance than green squares indicating susceptibility. This humorous comment reflected the serious reality that many institutions face increasingly limited therapeutic options across multiple organism categories.

Long-term care facilities have emerged as important reservoirs for resistant organisms. Residents frequently have multiple comorbidities, receive repeated antibiotic courses, and may harbor resistant organisms for extended periods. Transfer between acute care hospitals and long-term care facilities can facilitate the spread of pan-resistant organisms across healthcare networks.

International travel and medical tourism contribute to the global dissemination of resistance genes. Patients who receive medical care in regions with high resistance prevalence may acquire resistant organisms and introduce them to new geographic areas. This pattern has been documented with various carbapenemase-producing organisms.

The role of the environment in the dissemination of resistance requires consideration. Hospital surfaces, medical devices, and water systems can harbor resistant organisms. Environmental contamination can persist for extended periods, particularly with Acinetobacter species, which demonstrate remarkable survival capabilities outside the human host.

Surveillance systems worldwide track the emergence and spread of pan-resistant organisms. The CDC’s Antibiotic Resistance Laboratory Network monitors carbapenem-resistant organisms in the United States. European surveillance systems, including EARS-Net, track resistance patterns across member countries. These systems provide critical data to understand resistance trends and guide public health responses.

Clinical Manifestations and Patient Outcomes

Pan-resistant gram-negative infections present with clinical manifestations similar to those caused by susceptible organisms, but patient outcomes are substantially worse. The inability to provide effective antimicrobial therapy leads to prolonged infections, increased morbidity, and elevated mortality rates.

Bloodstream infections caused by pan-resistant gram-negatives carry particularly poor prognoses. Mortality rates frequently exceed 50%, with some studies reporting rates approaching 70%. The lack of effective treatment options means that patients may receive antibiotics with minimal or no activity against the infecting organism. Delayed effective therapy correlates directly with worse outcomes.

Ventilator-associated pneumonia represents another common manifestation of pan-resistant gram-negative infections. These infections typically occur in critically ill patients who already face an elevated baseline mortality risk. Pan-resistant P. aeruginosa and A. baumannii are frequent causes of these infections. Treatment options may be limited to experimental combinations or investigational agents available through compassionate use protocols.

Urinary tract infections caused by pan-resistant organisms present unique challenges. While urinary tract infections generally carry lower mortality rates than bloodstream infections, pan-resistant organisms can cause ascending infections leading to bacteremia and sepsis. Treatment options may include local irrigation with antimicrobials not suitable for systemic use or experimental combination therapies.

Surgical site infections and complex intra-abdominal infections caused by pan-resistant organisms require aggressive source control measures. Surgical intervention becomes even more critical when effective antimicrobial therapy is unavailable. Multiple debridement procedures may be necessary, and healing is often delayed.

The psychological impact on patients and families should not be underestimated. Isolation precautions necessary to prevent transmission can lead to social isolation and depression. Families may struggle to understand how modern medicine cannot provide effective treatment for their loved one’s infection.

Healthcare providers face ethical dilemmas when treating patients with pan-resistant infections. The decision to continue aggressive care versus transitioning to comfort measures requires careful consideration of the patient’s wishes, prognosis, and quality of life. These discussions are complicated by uncertainty about treatment efficacy and potential for recovery.

Length of hospital stay increases substantially for patients with pan-resistant infections. Extended hospitalizations result from delayed clinical improvement, the need for prolonged treatment courses, and complications associated with ineffective therapy. The economic burden on healthcare systems is substantial, with costs often exceeding those of susceptible infections by several-fold.

Current Treatment Approaches and Limitations

The treatment of pan-resistant gram-negative infections requires creative approaches and acceptance of therapeutic uncertainty. Traditional evidence-based medicine principles become challenging to apply when facing organisms resistant to all standard treatment options.

Combination antibiotic therapy represents the most common approach to pan-resistant infections. The rationale is to use multiple agents with different mechanisms of action to achieve bacterial killing despite individual drug resistance. Common combinations include polymyxins with carbapenems, tigecycline with aminoglycosides, or beta-lactam/beta-lactamase inhibitor combinations with fluoroquinolones.

Polymyxins, particularly colistin and polymyxin B, serve as backbone agents for many treatment regimens. These antibiotics were largely abandoned decades ago due to nephrotoxicity and neurotoxicity concerns. Their renewed use reflects the desperate need for options against pan-resistant gram-negative bacteria. Dosing optimization and therapeutic drug monitoring help maximize efficacy while minimizing toxicity.

High-dose, prolonged-infusion beta-lactam therapy aims to overcome resistance by optimizing pharmacokinetics. Extended or continuous infusions maintain drug concentrations above the minimum inhibitory concentration for longer periods. This approach may provide clinical benefit even when standard susceptibility testing suggests resistance.

Tigecycline represents another option for certain pan-resistant infections. This glycylcycline antibiotic demonstrates activity against many resistant gram-negatives, though resistance can develop rapidly. Its use is limited by poor pharmacokinetics for bloodstream infections and the potential for resistance emergence during therapy.

Aminoglycosides may retain activity against some pan-resistant organisms, particularly those without aminoglycoside-modifying enzymes or 16S rRNA methylation. High-dose aminoglycoside therapy, often administered once daily, can provide clinical benefit when combined with other agents. Careful monitoring for nephrotoxicity and ototoxicity is essential.

The limitations of current treatment approaches are substantial. Most combination therapies lack robust clinical data supporting their use. Treatment decisions often rely on in vitro susceptibility testing that may not accurately predict clinical outcomes. The potential for antagonistic interactions between antibiotics adds another layer of complexity.

Resistance emergence during therapy represents a major concern. Pan-resistant organisms have already demonstrated remarkable adaptability. Exposure to combination therapies may select for even more resistant subpopulations. The clinical implications of resistance development during treatment are profound, as no backup treatment options exist.

Toxicity from combination regimens can be substantial. The use of multiple potentially toxic agents increases the risk of adverse effects. Nephrotoxicity is particularly concerning given that many patients with pan-resistant infections already have compromised renal function from underlying illness or previous antibiotic exposures.

Emerging Therapeutic Strategies

The pipeline of new therapeutic approaches for pan-resistant gram-negatives includes novel antibiotics, combination products, and alternative treatment modalities. While none of these approaches provides a complete solution, they offer hope for improved outcomes in these challenging infections.

New beta-lactam/beta-lactamase inhibitor combinations target carbapenemase-producing organisms. Ceftazidime-avibactam demonstrates activity against KPC-producing Enterobacteriaceae and some OXA-producing organisms. Meropenem-vaborbactam shows promise against KPC-producing organisms. These combinations expand treatment options but remain vulnerable to certain resistance mechanisms.

Novel beta-lactamase inhibitors in development target metallo-beta-lactamases, which are not inhibited by current commercially available inhibitors. Combination products pairing these inhibitors with existing beta-lactams could restore activity against NDM and VIM-producing organisms. Clinical development programs for several such combinations are ongoing.

Cefiderocol represents a novel siderophore cephalosporin designed to overcome multiple resistance mechanisms. This agent uses bacterial iron transport systems to gain entry into gram-negative bacteria, potentially bypassing efflux pumps and porin modifications. Clinical trials have demonstrated activity against many pan-resistant organisms, though resistance can still occur.

Alternative mechanisms of action are being explored through novel antibiotic classes. Compounds targeting bacterial cell division, DNA replication, or metabolic pathways may avoid existing resistance mechanisms. However, the development timelines for these agents are measured in decades rather than years.

Bacteriophage therapy represents a completely different approach to treating bacterial infections. Phages are viruses that specifically target and kill bacteria. This approach has shown promise in case reports of pan-resistant infections, though regulatory pathways and manufacturing challenges remain significant barriers to widespread implementation.

Immunomodulatory approaches attempt to boost host immune responses against resistant bacteria. These strategies include cytokine therapies, immunoglobulins, and vaccines. While promising in theory, clinical evidence for efficacy remains limited.

Combination approaches using antimicrobials with non-antibiotic compounds show potential. Agents that inhibit efflux pumps, disrupt biofilms, or sensitize bacteria to immune clearance could restore the activity of existing antibiotics. Several such combinations are in early-stage development.

The challenges facing new therapeutic development are substantial. The relatively small market for agents targeting pan-resistant infections creates economic disincentives for pharmaceutical development. Regulatory pathways for novel approaches, such as phage therapy, remain unclear. The timeline for bringing new agents from discovery to clinical use often spans 10-15 years.

Prevention and Infection Control Strategies

Preventing the emergence and spread of pan-resistant gram-negatives requires coordinated efforts across multiple domains. Infection control measures, antimicrobial stewardship, and surveillance systems all play critical roles in addressing this challenge.

Contact precautions represent the cornerstone of infection control for pan-resistant organisms. These measures include patient isolation, use of personal protective equipment, and dedicated medical equipment. The effectiveness of contact precautions depends on strict adherence by all healthcare personnel, which can be challenging to maintain consistently.

Active surveillance screening helps identify patients colonized with pan-resistant organisms before clinical infection develops. Rectal swabs can detect carbapenemase-producing Enterobacteriaceae, while respiratory or wound cultures may identify resistant Pseudomonas or Acinetobacter species. Early identification allows for prompt implementation of infection control measures.

Environmental cleaning and disinfection require special attention in areas where pan-resistant organisms have been identified. Some organisms, particularly Acinetobacter species, can survive on surfaces for extended periods. Enhanced cleaning protocols, using appropriate disinfectants and increasing cleaning frequency, help reduce environmental contamination.

Antimicrobial stewardship programs play a crucial role in preventing the development of antimicrobial resistance. Appropriate antibiotic selection, dosing, and duration help minimize selective pressure that favors the emergence of resistant organisms. Restriction of certain high-risk antibiotics, such as carbapenems and fluoroquinolones, may help preserve their effectiveness.

The concept of antimicrobial cycling, where specific antibiotic classes are rotated in and out of use, has been proposed as a strategy to prevent resistance. However, clinical evidence supporting this approach is mixed, and implementation challenges make it difficult to execute effectively.

Education of healthcare personnel is essential for effective prevention programs. Understanding the mechanisms of resistance transmission, the proper use of infection control measures, and the principles of antimicrobial stewardship helps create a culture of resistance prevention. Regular training and reinforcement help maintain awareness and compliance.

Patient and family education contributes to prevention efforts. Understanding the importance of hand hygiene, compliance with isolation measures, and appropriate antibiotic use helps engage patients as partners in prevention. Clear communication about the risks of resistance helps motivate adherence to prevention measures.

Economic and Healthcare System Impact

The economic burden of pan-resistant gram-negative infections extends far beyond direct treatment costs. Healthcare systems face substantial financial pressures from these infections, including increased length of stay, enhanced infection control measures, and the development of specialized treatment protocols.

Direct medical costs for treating pan-resistant infections often exceed those for susceptible infections by two to threefold. Extended hospitalizations result from delayed clinical improvement, need for prolonged antibiotic courses, and management of complications. Intensive care unit stays are frequently prolonged, adding substantial daily costs.

The cost of new antibiotics adds another economic dimension. Novel agents developed for resistant organisms often carry premium pricing reflecting their specialized use and development costs. Healthcare systems must balance the clinical need for these agents against budget constraints and formulary considerations.

Infection control measures required for pan-resistant organisms create ongoing expenses. Single-room isolation reduces hospital capacity by preventing the use of multi-patient rooms. Enhanced cleaning protocols require additional staff time and specialized disinfectants. Personal protective equipment costs increase with isolation precautions.

Laboratory costs for resistance detection and monitoring add to the economic burden. Specialized testing for carbapenemase production, molecular resistance mechanisms, and combination susceptibility testing requires expensive equipment and trained personnel. Rapid diagnostic testing, while potentially improving outcomes, often comes at premium pricing.

The impact on healthcare worker productivity should not be overlooked. Time spent on enhanced infection control measures, obtaining specialized antibiotics, and managing complex treatment regimens reduces efficiency. The psychological stress of caring for patients with untreatable infections can contribute to burnout and turnover.

Legal and regulatory compliance costs associated with resistant organism management include reporting requirements, outbreak investigations, and quality improvement initiatives. These activities require dedicated personnel time and resources that could otherwise be directed toward patient care.

The broader economic impact extends to lost productivity from patients who experience prolonged illnesses or poor outcomes. Family members may miss work to provide care or support during extended hospitalizations. The societal cost of antimicrobial resistance includes these indirect economic effects.

Future Research Directions and Innovative Approaches

The challenge of pan-resistant gram-negatives requires sustained research efforts across multiple disciplines. Current research directions span from basic science investigations of resistance mechanisms to clinical trials of novel therapeutic approaches.

Understanding the molecular mechanisms driving pan-resistance remains a priority. Advanced genomic sequencing techniques allow for real-time analysis of resistance gene acquisition and evolution. This knowledge helps predict trends in resistance and identify potential targets for intervention.

Pharmacokinetic and pharmacodynamic research focuses on optimizing the use of existing antibiotics against resistant organisms. Studies of combination therapy synergy, dosing strategies, and drug delivery systems may improve outcomes with currently available agents. Mathematical modeling helps predict optimal dosing regimens for combination therapies.

Novel antibiotic discovery efforts target unique bacterial pathways not affected by current resistance mechanisms. Advances in screening techniques, synthetic biology, and artificial intelligence accelerate the identification of promising compounds. However, the timeline from discovery to clinical use remains lengthy.

Diagnostic development aims to provide rapid identification of resistance mechanisms and guide targeted therapy. Point-of-care testing for specific resistance genes could enable real-time treatment decisions. Phenotypic testing methods that rapidly assess antibiotic combination synergy show promise for personalizing therapy.

Immunotherapy approaches under investigation include passive immunization with specific antibodies, active vaccination against resistant organisms, and modulation of the immune system. These strategies could complement antimicrobial therapy or provide alternatives when antibiotics fail.

Microbiome research explores how pan-resistant organisms interact with normal bacterial flora. Understanding these interactions may identify ways to prevent colonization or promote clearance of resistant organisms. Fecal microbiota transplantation has shown promise for eliminating resistant Enterobacteriaceae in some patients.

Mathematical modeling and artificial intelligence applications help predict patterns of resistance emergence, optimize treatment combinations, and design prevention strategies. Machine learning algorithms can analyze large datasets to identify factors associated with resistance development or successful treatment outcomes.

 

Frequently Asked Questions

Q: What exactly does “pan-resistant” mean in clinical practice?

A: Pan-resistant bacteria show resistance to all antibiotics tested in standard laboratory panels. This means there are no proven effective antibiotic options available for treating infections caused by these organisms. Doctors may try combination therapies or experimental approaches, but there is no guarantee they will work.

Q: How do bacteria become pan-resistant?

A: Pan-resistance develops when bacteria acquire multiple resistance mechanisms simultaneously. This usually happens over time through exposure to various antibiotics, which selects for organisms with the most resistance genes. Bacteria can share resistance genes, allowing the rapid spread of resistance traits.

Q: Which patients are most at risk for pan-resistant infections?

A: Patients at highest risk include those in intensive care units, individuals with prolonged hospital stays, patients who have received multiple antibiotic courses, and those with invasive medical devices like ventilators or catheters. People with weakened immune systems also face increased risk.

Q: Can pan-resistant infections be cured?

A: Some patients do recover from pan-resistant infections, but cure rates are much lower than with susceptible bacteria. Recovery often depends on the patient’s immune system, the infection site, and whether source control (like surgical drainage) is possible. Many patients do not survive these infections despite aggressive treatment.

Q: Are there new antibiotics being developed for pan-resistant bacteria?

A: Yes, several new antibiotics are in development, specifically targeting resistant gram-negative bacteria. These include new beta-lactam combinations, novel antibiotic classes, and innovative approaches such as bacteriophage therapy. However, most are still years away from being available to patients.

Q: How can hospitals prevent the spread of pan-resistant bacteria?

A: Prevention strategies include strict contact isolation for infected patients, enhanced hand hygiene, environmental cleaning with appropriate disinfectants, active screening of high-risk patients, and careful antibiotic stewardship programs. Staff education and compliance monitoring are essential for success.

Q: Should I be worried about getting a pan-resistant infection during routine medical care?

A: The risk for healthy individuals receiving routine outpatient care is very low. Pan-resistant infections primarily occur in hospitalized patients, especially those who are critically ill or have been in healthcare facilities for extended periods. Following basic hygiene practices and taking antibiotics only when prescribed helps reduce risk.

Q: What should families expect if their loved one has a pan-resistant infection?

A: Families should expect extended hospitalizations, isolation precautions that limit visiting, and uncertainty about treatment outcomes. Healthcare teams will try various treatment approaches, but may not achieve the definitive cure rates typically expected with antibiotic therapy. Open communication with medical teams about goals of care is important.

Q: Are pan-resistant infections becoming more common?

A: Yes, reports of pan-resistant gram-negative infections are increasing worldwide. However, they still account for only a small percentage of all bacterial infections. The concern is that this percentage is growing, and these infections are becoming more common in certain healthcare settings.

Q: What can individual doctors do when faced with a pan-resistant infection?

A: Physicians should consult infectious disease specialists, consider combination antibiotic therapies based on available susceptibility data, ensure appropriate source control measures, and explore access to investigational agents through compassionate use programs. Engaging in honest discussions with patients and families about prognosis is also important.

References

Bassetti, M., Righi, E., Carnelutti, A., Graziano, E., & Russo, A. (2018). Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention, and infection control. Expert Review of Anti-Infective Therapy, 16(10), 749-761.

Bonomo, R. A., Burd, E. M., Conly, J., Limbago, B. M., Poirel, L., Segre, J. A., & Westblade, L. F. (2018). Carbapenemase-producing organisms: a global scourge. Clinical Infectious Diseases, 66(8), 1290-1297.

Bulman, Z. P., Chen, L., Walsh, T. J., Satlin, M. J., Qureshi, N. K., Chavda, K. D., … & Kreiswirth, B. N. (2017). Polymyxin combinations combat the emergence of polymyxin resistance in Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 61(4), e00755-16.

Centers for Disease Control and Prevention. (2019). Antibiotic resistance threats in the United States, 2019. U.S. Department of Health and Human Services, CDC.

Dadashi, M., Nasiri, M. J., Fallah, F., Owlia, P., Hajikhani, B., Emaneini, M., & Mirpour, M. (2019). Methicillin-resistant Staphylococcus aureus (MRSA) in Iran: a systematic review and meta-analysis. Journal of Global Antimicrobial Resistance, 12, 96-103.

Falagas, M. E., Lourida, P., Poulikakos, P., Rafailidis, P. I., & Tansarli, G. S. (2014). Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrobial Agents and Chemotherapy, 58(2), 654-663.

Garnacho-Montero, J., Timsit, J. F., Seifert, H., Dimopoulos, G., Bassetti, M., Rello, J., & Kollef, M. H. (2019). Outcomes of Acinetobacter baumannii HAP/VAP treatment with cefiderocol: insights from the CREDIBLE-CR study. European Respiratory Journal, 54(suppl 63), PA2710.

Giacobbe, D. R., Giani, T., Bassetti, M., Marchese, A., Viscoli, C., Rossolini, G. M., & ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). (2018). Rapid microbiological tests for bloodstream infections due to multidrug resistant Gram-negative bacteria: therapeutic implications. Clinical Microbiology and Infection, 24(1), 24-31.

Haidar, G., Clancy, C. J., Shields, R. K., Hao, B., Cheng, S., & Nguyen, M. H. (2017). Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum β-lactamases. Antimicrobial Agents and Chemotherapy, 61(5), e02534-16.

Karampatakis, T., Tsergouli, K., & Behzadi, P. (2023). Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. Clinical Microbiology and Infection, 29(4), 456-462.

Lutgring, J. D., & Limbago, B. M. (2016). The problem of carbapenemase-producing-carbapenem-resistant-Enterobacteriaceae detection. Journal of Clinical Microbiology, 54(3), 529-534.

Magiorakos, A. P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., … & Monnet, D. L. (2012). Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection, 18(3), 268-281.

Nordmann, P., Naas, T., & Poirel, L. (2011). Global spread of carbapenemase-producing Enterobacteriaceae. Emerging Infectious Diseases, 17(10), 1791-1798.

Papp-Wallace, K. M., Endimiani, A., Taracila, M. A., & Bonomo, R. A. (2011). Carbapenems: past, present, and future. Antimicrobial Agents and Chemotherapy, 55(11), 4943-4960.

Paul, M., Carrara, E., Retamar, P., Tängdén, T., Bitterman, R., Bonomo, R. A., … & Leibovici, L. (2018). European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clinical Microbiology and Infection, 24(2), 81-88.

Perez, F., & Bonomo, R. A. (2019). Carbapenem-resistant Enterobacteriaceae: global action required. The Lancet Infectious Diseases, 19(6), 561-562.

Pitout, J. D., Nordmann, P., & Poirel, L. (2015). Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrobial Agents and Chemotherapy, 59(10), 5873-5884.

Poirel, L., Jayol, A., & Nordmann, P. (2017). Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clinical Microbiology Reviews, 30(2), 557-596.

Santajit, S., & Indrawattana, N. (2016). Mechanisms of antimicrobial resistance in ESKAPE pathogens. BioMed Research International, 2016, 2475067.

Shields, R. K., Nguyen, M. H., Chen, L., Press, E. G., Potoski, B. A., Marini, R. V., … & Clancy, C. J. (2017). Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrobial Agents and Chemotherapy, 61(8), e00883-17.

Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., … & WHO Pathogens Priority List Working Group. (2018). Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. The Lancet Infectious Diseases, 18(3), 318-327.

Tamma, P. D., Goodman, K. E., Harris, A. D., Tekle, T., Roberts, A., Taiwo, A., & Simner, P. J. (2017). Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia. Clinical Infectious Diseases, 64(3), 257-264.

van Duin, D., Lok, J. J., Earley, M., Cober, E., Richter, S. S., Perez, F., … & Antibacterial Resistance Leadership Group. (2018). Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clinical Infectious Diseases, 66(2), 163-171.

Woodford, N., Turton, J. F., & Livermore, D. M. (2011). Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiology Reviews, 35(5), 736-755.

World Health Organization. (2017). Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Geneva: World Health Organization.

Zasowski, E. J., Rybak, J. M., & Rybak, M. J. (2015). The β-lactams strike back: ceftazidime-avibactam. Pharmacotherapy, 35(8), 755-770.